Personalis, Inc.

Equities

PSNL

US71535D1063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.265 ^USD	+1.20%		-1.94%	-39.76%

Mar. 26	Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring	CI
Feb. 29	Needham Raises Price Target on Personalis to $3.50 From $2.30, Maintains Buy Rating	MT

Personalis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 28, 2024 at 04:15 pm EST

Personalis, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 73.48 million compared to USD 65.05 million a year ago. Net loss was USD 108.3 million compared to USD 113.32 million a year ago.

Basic loss per share from continuing operations was USD 2.25 compared to USD 2.48 a year ago. Diluted loss per share from continuing operations was USD 2.25 compared to USD 2.48 a year ago.

Latest news about Personalis, Inc.

Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring	Mar. 26	CI
Needham Raises Price Target on Personalis to $3.50 From $2.30, Maintains Buy Rating	Feb. 29	MT
Transcript : Personalis, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Personalis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Earnings Flash (PSNL) PERSONALIS Reports Q4 Revenue $19.7M, vs. Street Est of $19.3M	Feb. 28	MT
Personalis, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024	Feb. 28	CI
Personalis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Personalis to Offer ClearNote's Epigenomic Platform in Partnership	Jan. 30	MT
Personalis, Inc. and ClearNote Health, Inc. Announce Partnership to Advance Epigenomic Technology	Jan. 30	CI
Personalis Announces Medicare Coverage for Next Dx(R) Comprehensive Genomic Tumor Profiling Assay	Jan. 16	CI
Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	Jan. 05	CI
Personalis, Tempus Labs to Collaborate on NeXT Personal Dx Detection Test	Nov. 28	MT
Personalis and Tempus Enter into Strategic Collaboration to Advance Cancer Testing	Nov. 28	CI
Myriad Genetics, Personalis Collaborate to Market ImmunoID NeXT Platform	Nov. 16	MT
Myriad Genetics, Inc. and Personalis, Inc. Partner to Market Solutions to Pharma Customers	Nov. 16	CI
Needham Cuts Price Target on Personalis to $2.30 From $7, Maintains Buy Rating	Nov. 08	MT
Transcript : Personalis, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Personalis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Earnings Flash (PSNL) PERSONALIS Posts Q3 Revenue $18.2M, vs. Street Est of $17M	Nov. 07	MT
Personalis, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023	Nov. 07	CI
Personalis, Inc. Revises Earnings Guidance for the Full Year 2023	Nov. 07	CI
Personalis, Inc. Launches NeXT Personal DX for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer	23-10-26	CI
Transcript : Personalis, Inc. - Special Call	23-10-24
Personalis, Inc. Announces the Presentation of Initial Findings from Its Work with the Tracerx Lung Cancer Study	23-10-21	CI
Personalis, Inc. Appoints Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance	23-10-19	CI

Chart Personalis, Inc.

Duration

Period

More charts

Company Profile

Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Companyâs advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Companyâs tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Personalis, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.265 USD

Average target price

4.75 USD

Spread / Average Target

+275.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PERSONALIS, INC.	-39.76%	64.78M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research